Triton Market Research’s report on the Latin American CRISPR market illustrates that the market will augment at a CAGR of 22.37% in the forecasted years 2019-2028.
The countries reviewed in the Latin American CRISPR market are:
• Mexico
• Brazil
• Rest of Latin America
In Brazil, genetically-edited crops are considered as conventional plants unless they contain any foreign DNA. According to the changes that were introduced in January 2018, it was concluded that NBTs (New Breeding Techniques) could not be regulated as transgenic GMOs (genetically modified organisms) if no genes are retained from foreign species. The National Technical Commission sets safety standards for genetically modified organisms (GMOs). Furthermore, the Brazilian company Tropical Melhoramento & Genética has collaborated with an Israeli company Evogene to develop a parasite-resistant soybean, using gene-editing tools like CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats). The growing CRISPR procedures in the country are expected to drive the market during the forthcoming period.
In Mexico, human genome editing and human genetic engineering are not explicitly regulated. However, all applications of CRISPR technology must be monitored, and procedures, not safety-tested in humans must be penalized. Also, Mexico is known as a center of origin for various economically important plants, such as maize, cocoa and cotton. Crops such as soybean, maize and cotton have been genetically engineered in order to tolerate and resist insect pests and herbicides, among others. Such developmental initiatives indicate the growth of the CRISPR market in the country.
Established in 1974, New England Biolabs is a US-based company engaged in the field of discovery, development and marketing of native enzymes for genomic research. The company provides different products and services, including reagents, antibodies, enzymes and DNA controls for protein expression & purification technologies, protein tools, epigenetics research, glycobiology products & plasmids and DNAs for cloning experiments. The company is active in different regions, including Latin America.
Some of the key companies in the CRISPR market are Intellia Therapeutics Inc, Cellectis, Sigma-Aldrich (Merck KGaA), GenScript, New England Biolabs, GeneCopoeia Inc, Origene Technologies Inc, Addgene, Horizon Discovery Ltd, Applied StemCell, Thermo Fisher Scientific Inc, Editas Medicine, DiaCarta, Caribou Biosciences Inc, Sangamo Therapeutics, Transposagen Bio (Hera BioLabs), Genedata AG, Precision Biosciences, Lonza, Integrated DNA Technologies Inc and CRISPR Therapeutics.